Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
121,543,157
-
Number of holders
-
92
-
Total 13F shares, excl. options
-
58,119,888
-
Shares change
-
+2,119,709
-
Total reported value, excl. options
-
$194,118,470
-
Value change
-
+$7,244,002
-
Put/Call ratio
-
4%
-
Number of buys
-
46
-
Number of sells
-
21
-
Price
-
$3.34
Institutional Holders of Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (TRVI) as of Q3 2024
As of 30 Sep 2024 Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (TRVI) had 99 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 58,119,888 shares of stock of the company.
Largest 10 holders included NEA Management Company, LLC, Frazier Life Sciences Management, L.P., Rubric Capital Management LP, VIKING GLOBAL INVESTORS LP, VR Adviser, LLC, VANGUARD GROUP INC, BlackRock, Inc., Logos Global Management LP, Opaleye Management Inc., and Vivo Capital, LLC.
This table shows 99 institutional shareholders of the security as of 30 Sep 2024.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.